Reducing reperfusion injury during percutaneous coronary intervention

Huang, Mengting; Loh, Poay Huan; Tan, Huay Cheem; Poh, Kian Keong

doi:10.11622/smedj.2019157

Cited by 2 publications

(1 citation statement)

References 13 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large CathPCI registry analysis found that median DTB time improvement of 83 to 67 min from 2005 to 2009 was not associated with improved in-hospital mortality rates [15]. In recent years, more practitioners have begun to discuss the persistent need to improve performance on other metrics beyond DTB times and reducing ischemic injury -such as reduction in reperfusion injury -in order to further improve STEMI survival outcomes [16][17][18][19]. As flat mortality rates despite improving DTB times have identified, a successful STEMI treatment strategy must involve consideration of more granular metrics as relates to reperfusion timing and efficacy.…”

Section: Reperfusion Injurymentioning

confidence: 99%

Door-to-unload: Left Ventricular Unloading Before Reperfusion in ST-elevation Myocardial Infarction

et al. 2021

View full text Add to dashboard Cite

ST-elevation myocardial infarction treatment in the modern era has focused on minimizing time of ischemia by reducing door-to-balloon time to limit infarct size and improve survival. Although there have been significant improvements in minimizing time to coronary reperfusion, the incidence of heart failure following a myocardial infarction has remained high. Preclinical studies have shown that unloading the left ventricle for 30 min prior to coronary reperfusion can reduce infarct size and promote myocardial recovery. The DTU-STEMI randomized prospective trial will test the hypothesis that left ventricular unloading for at least 30 min prior to coronary reperfusion will improve infarct size and heart failure-related events as compared with the current standard of care.

show abstract

Section: Reperfusion Injurymentioning

confidence: 99%

Door-to-unload: Left Ventricular Unloading Before Reperfusion in ST-elevation Myocardial Infarction

et al. 2021

View full text Add to dashboard Cite

show abstract

Reactive Oxygen Species Scavenging Nanomedicine for the Treatment of Ischemic Heart Disease

Zhang

Dalan

et al. 2022

Advanced Materials

View full text Add to dashboard Cite

Ischemic heart disease (IHD) is the leading cause of disability and mortality worldwide. Reactive oxygen species (ROS) have been shown to play key roles in the progression of diabetes, hypertension, and hypercholesterolemia, which are independent risk factors that lead to atherosclerosis and the development of IHD. Engineered biomaterial‐based nanomedicines are under extensive investigation and exploration, serving as smart and multifunctional nanocarriers for synergistic therapeutic effect. Capitalizing on cell/molecule‐targeting drug delivery, nanomedicines present enhanced specificity and safety with favorable pharmacokinetics and pharmacodynamics. Herein, the roles of ROS in both IHD and its risk factors are discussed, highlighting cardiovascular medications that have antioxidant properties, and summarizing the advantages, properties, and recent achievements of nanomedicines that have ROS scavenging capacity for the treatment of diabetes, hypertension, hypercholesterolemia, atherosclerosis, ischemia/reperfusion, and myocardial infarction. Finally, the current challenges of nanomedicines for ROS‐scavenging treatment of IHD and possible future directions are discussed from a clinical perspective.

show abstract

Reducing reperfusion injury during percutaneous coronary intervention

Cited by 2 publications

References 13 publications

Door-to-unload: Left Ventricular Unloading Before Reperfusion in ST-elevation Myocardial Infarction

Door-to-unload: Left Ventricular Unloading Before Reperfusion in ST-elevation Myocardial Infarction

Reactive Oxygen Species Scavenging Nanomedicine for the Treatment of Ischemic Heart Disease

Contact Info

Product

Resources

About